Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 57
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Acta Psychiatr Scand ; 137(3): 176-186, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29266167

RESUMEN

OBJECTIVE: We aimed at determining whether gender modified associations between ADHD and psychiatric comorbidities in adults. METHOD: We identified adults with ADHD by linking Norwegian national registries and compared them with the remaining adult population (born 1967-1997, ADHD and bipolar during 2004-2015, other psychiatric disorders 2008-2015). Prevalence differences (PDs) and prevalence ratios (PRs) of psychiatric disorders were determined by Poisson regression. Interaction by gender was evaluated on additive (PDs) and multiplicative (PRs) scales. Proportions of psychiatric disorders attributable to ADHD were calculated. RESULTS: We identified 40 103 adults with ADHD (44% women) and 1 661 103 adults (49% women) in the remaining population. PDs associated with ADHD were significantly larger in women than in men for anxiety, depression, bipolar and personality disorders, for example depression in women: 24.4 (95% CI, 23.8-24.9) vs. in men: 13.1 (12.8-13.4). PDs were significantly larger in men for schizophrenia and substance use disorder (SUD), for example SUD in men: 23.0 (22.5-23.5) vs. in women: 13.7 (13.3-14.0). Between 5.6 and 16.5% of psychiatric disorders in the population were attributable to ADHD. CONCLUSION: The association between ADHD and psychiatric comorbidities differed significantly among men and women. Clinicians treating adults with ADHD should be aware of these frequent and gender-specific comorbidities, such that early treatment can be offered.


Asunto(s)
Trastornos de Ansiedad/epidemiología , Trastorno por Déficit de Atención con Hiperactividad/epidemiología , Trastorno Bipolar/epidemiología , Trastorno Depresivo/epidemiología , Trastornos de la Personalidad/epidemiología , Sistema de Registros/estadística & datos numéricos , Esquizofrenia/epidemiología , Trastornos Relacionados con Sustancias/epidemiología , Adulto , Comorbilidad , Estudios Transversales , Femenino , Humanos , Masculino , Noruega/epidemiología , Prevalencia , Factores Sexuales , Adulto Joven
2.
Eur J Clin Pharmacol ; 74(4): 513-520, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29230493

RESUMEN

PURPOSE: Pregnancy prevention programmes (PPPs) exist for some medicines known to be highly teratogenic. It is increasingly recognised that the impact of these risk minimisation measures requires periodic evaluation. This study aimed to assess the extent to which some of the data needed to monitor the effectiveness of PPPs may be present in European healthcare databases. METHODS: An inventory was completed for databases contributing to EUROmediCAT capturing pregnancy and prescription data in Denmark, Norway, the Netherlands, Italy (Tuscany/Emilia Romagna), Wales and the rest of the UK, to determine the extent of data collected that could be used to evaluate the impact of PPPs. RESULTS: Data availability varied between databases. All databases could be used to identify the frequency and duration of prescriptions to women of childbearing age from primary care, but there were specific issues with availability of data from secondary care and private care. To estimate the frequency of exposed pregnancies, all databases could be linked to pregnancy data, but the accuracy of timing of the start of pregnancy was variable, and data on pregnancies ending in induced abortions were often not available. Data availability on contraception to estimate compliance with contraception requirements was variable and no data were available on pregnancy tests. CONCLUSION: Current electronic healthcare databases do not contain all the data necessary to fully monitor the effectiveness of PPP implementation, and thus, special data collection measures need to be instituted.


Asunto(s)
Anomalías Inducidas por Medicamentos/prevención & control , Anticoncepción/métodos , Bases de Datos Factuales , Embarazo no Planeado , Teratógenos , Anomalías Inducidas por Medicamentos/epidemiología , Aborto Inducido , Minería de Datos , Registros Electrónicos de Salud , Europa (Continente)/epidemiología , Femenino , Humanos , Registro Médico Coordinado , Cooperación del Paciente , Embarazo , Pruebas de Embarazo , Evaluación de Programas y Proyectos de Salud , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo
3.
BJOG ; 123(10): 1609-18, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27172856

RESUMEN

OBJECTIVE: To examine the effect of maternal exposure to asthma medications on the risk of congenital anomalies. DESIGN: Meta-analysis of aggregated data from three cohort studies. SETTING: Linkage between healthcare databases and EUROCAT congenital anomaly registries. POPULATION: 519 242 pregnancies in Norway (2004-2010), Wales (2000-2010) and Funen, Denmark (2000-2010). METHODS: Exposure defined as having at least one prescription for asthma medications issued (Wales) or dispensed (Norway, Denmark) from 91 days before to 91 days after the pregnancy start date. Odds ratios (ORs) were estimated separately for each register and combined in meta-analyses. MAIN OUTCOME MEASURES: ORs for all congenital anomalies and specific congenital anomalies. RESULTS: Overall exposure prevalence was 3.76%. For exposure to asthma medication in general, the adjusted OR (adjOR) for a major congenital anomaly was 1.21 (99% CI 1.09-1.34) after adjustment for maternal age and socioeconomic position. The OR of anal atresia was significantly increased in pregnancies exposed to inhaled corticosteroids (3.40; 99% CI 1.15-10.04). For severe congenital heart defects, an increased OR (1.97; 1.12-3.49) was associated with exposure to combination treatment with inhaled corticosteroids and long-acting beta-2-agonists. Associations with renal dysplasia were driven by exposure to short-acting beta-2-agonists (2.37; 1.20-4.67). CONCLUSION: The increased risk of congenital anomalies for women taking asthma medication is small with little confounding by maternal age or socioeconomic status. The study confirmed the association of inhaled corticosteroids with anal atresia found in earlier research and found potential new associations with combination treatment. The potential new associations should be interpreted with caution due to the large number of comparisons undertaken. TWEETABLE ABSTRACT: This cohort study found a small increased risk of congenital anomalies for women taking asthma medication.


Asunto(s)
Anomalías Inducidas por Medicamentos/epidemiología , Corticoesteroides/efectos adversos , Agonistas de Receptores Adrenérgicos beta 2/efectos adversos , Antiasmáticos/efectos adversos , Asma/tratamiento farmacológico , Complicaciones del Embarazo/epidemiología , Primer Trimestre del Embarazo , Proyectos de Investigación , Lesión Renal Aguda/epidemiología , Corticoesteroides/administración & dosificación , Agonistas de Receptores Adrenérgicos beta 2/administración & dosificación , Adulto , Aerosoles/efectos adversos , Antiasmáticos/administración & dosificación , Ano Imperforado/epidemiología , Estudios de Cohortes , Dinamarca/epidemiología , Femenino , Cardiopatías Congénitas/epidemiología , Humanos , Recién Nacido , Noruega/epidemiología , Embarazo , Efectos Tardíos de la Exposición Prenatal/epidemiología , Prevalencia , Sistema de Registros , Proyectos de Investigación/estadística & datos numéricos , Factores de Riesgo , Gales/epidemiología
4.
BJOG ; 122(12): 1618-24, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25395328

RESUMEN

OBJECTIVE: To assess whether the use of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, mirtazapine, venlafaxine or other antidepressants is associated with late elective termination of pregnancy. DESIGN: Case-control study using data from national registers. SETTING: Denmark, Finland, and Norway during the period 1996-2007. POPULATION: A total of 14,902 women were included as cases and 148,929 women were included as controls. METHODS: Cases were women with elective termination of pregnancy at 12-23 weeks of gestation. Controls continued their pregnancy and were matched with cases on key factors. MAIN OUTCOME MEASURES: Association between antidepressant use during pregnancy and elective termination of pregnancy at 12-23 weeks of gestation for fetal anomalies, or for maternal ill health or socio-economic disadvantage. RESULTS: At least one prescription of antidepressants was filled by 3.7% of the cases and 2.2% of the controls. Use of any type of antidepressant was associated with elective termination of pregnancy for maternal ill health or socio-economic disadvantage (odds ratio, OR 2.3; 95% confidence interval, 95% CI 2.0-2.5). Elective termination of pregnancy for fetal anomalies was associated with the use of mirtazapine (OR 2.2, 95% CI 1.1-4.5). There was no association between the use of any of the other antidepressants and elective termination of pregnancy for fetal anomalies. CONCLUSION: The use of any type of antidepressants was associated with elective termination of pregnancy at 12-23 weeks for maternal ill health or socio-economic disadvantage, but not with terminations for fetal anomalies. Further studies need to confirm the findings concerning mirtazapine and termination of pregnancy for fetal anomalies.


Asunto(s)
Aborto Inducido/psicología , Antidepresivos Tricíclicos/administración & dosificación , Antidepresivos/administración & dosificación , Depresión/tratamiento farmacológico , Mianserina/análogos & derivados , Inhibidores Selectivos de la Recaptación de Serotonina/administración & dosificación , Ultrasonografía Prenatal/estadística & datos numéricos , Aborto Inducido/estadística & datos numéricos , Adulto , Estudios de Casos y Controles , Dinamarca/epidemiología , Depresión/epidemiología , Depresión/etiología , Esquema de Medicación , Femenino , Finlandia/epidemiología , Humanos , Edad Materna , Mianserina/administración & dosificación , Mirtazapina , Noruega/epidemiología , Embarazo , Factores de Riesgo , Clase Social
5.
Eur J Neurol ; 21(7): 948-55, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24712740

RESUMEN

BACKGROUND AND PURPOSE: Comorbidity in myasthenia gravis (MG) is important for diagnosis, treatment and prognosis. Disease complexity was assessed by examining total drug treatment, immune therapy and comorbidity in a complete national MG cohort. METHODS: All recipients of the MG-specific drug pyridostigmine 2004-2010 registered in the compulsory Norwegian Prescription Database who met the inclusion criteria were included. The pyridostigmine group was compared with the general Norwegian population. RESULTS: Myasthenia gravis patients received co-medication more often than the controls for nearly all groups of medication, including insulins (95% confidence interval 2.0-3.7), thyroid therapy (1.7-2.5), antidepressants (1.3-1.7), anti-infectives (1.2-1.4), lipid-modifying agents (1.1-1.4) and immunomodulating agents (6.8-8.8). CONCLUSIONS: Myasthenia gravis patients are more often treated with non-MG prescription drugs than controls, reflecting frequent co-medication and comorbidity.


Asunto(s)
Comorbilidad , Prescripciones de Medicamentos/estadística & datos numéricos , Miastenia Gravis/tratamiento farmacológico , Bromuro de Piridostigmina/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Miastenia Gravis/epidemiología , Noruega/epidemiología , Adulto Joven
6.
Br J Cancer ; 108(7): 1525-33, 2013 Apr 16.
Artículo en Inglés | MEDLINE | ID: mdl-23481179

RESUMEN

BACKGROUND: As the number of cancer survivors increases, their health and welfare have come into focus. Thus, long-term medical consequences of cancer at a young age (<25 years), obtained from social security benefit records, were studied. METHODS: Standardised incidence ratios (SIRs) of long-term medical consequences for 5-year cancer survivors, born during 1965-1985, were explored by linking population-based registries in Norway. RESULTS: Among the 5-year cancer survivors (4031 individuals), 29.7% received social security benefits. The survivors had an overall 4.4 times (95% confidence interval (95% CI): 4.1-4.6) higher risk of social security benefit uptake than the cancer-free population. Survivors of malignancies of bone and connective tissues (SIR: 10.8; 95% CI: 9.1-12.9), CNS tumours (SIR: 7.7; 95% CI: 6.9-8.6) and malignancies of the haematopoietic system (SIR: 6.1; 95% CI: 5.3-7.0) had the highest risks of social security benefits uptake. The most notified causes of social security benefit uptake were diseases of the nervous system, and injury and poisoning. CONCLUSION: The uptake of social security benefits among 5-year cancer survivors increased substantially and it may represent a solid outcome measure for the burden of the most severe late effects, especially in countries with comparable social welfare systems.


Asunto(s)
Neoplasias/economía , Seguridad Social/estadística & datos numéricos , Sobrevivientes/estadística & datos numéricos , Adolescente , Niño , Preescolar , Estudios de Cohortes , Femenino , Humanos , Lactante , Masculino , Neoplasias/epidemiología , Noruega/epidemiología , Adulto Joven
7.
Br J Dermatol ; 167(1): 59-67, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22530854

RESUMEN

BACKGROUND: Little is known about the associations of metabolic aberrations with malignant melanoma (MM) and nonmelanoma skin cancer (NMSC). OBJECTIVES: To assess the associations between metabolic factors (both individually and combined) and the risk of skin cancer in the large prospective Metabolic Syndrome and Cancer Project (Me-Can). METHODS: During a mean follow-up of 12 years of the Me-Can cohort, 1728 (41% women) incident MM, 230 (23% women) fatal MM and 1145 (33% women) NMSC were identified. Most NMSC cases (76%) were squamous cell carcinoma (SCC) (873, 33% women). Hazard ratios (HRs) were estimated by Cox proportional hazards regression for quintiles and standardized z-scores (with a mean of 0 and SD of 1) of body mass index (BMI), blood pressure, glucose, cholesterol, triglycerides and for a combined metabolic syndrome score. Risk estimates were corrected for random error in the measurements. RESULTS: Blood pressure per unit increase of z-score was associated with an increased risk of incident MM cases in men and women [HR 1·17, 95% confidence interval (CI) 1·04-1·31 and HR 1·18, 95% CI 1·03-1·36, respectively] and fatal MM cases among women (HR 2·39, 95% CI 1·58-3·64). In men, all quintiles for BMI above the reference were associated with a higher risk of incident MM. In women, SCC NMSC risk increased across quintiles for glucose levels (P-trend 0·02) and there was a trend with triglyceride concentration (P-trend 0·09). CONCLUSION: These findings suggest that mechanisms linked to blood pressure may be involved in the pathogenesis of MM. SCC NMSC in women could be related to glucose and lipid metabolism.


Asunto(s)
Melanoma/etiología , Síndrome Metabólico/complicaciones , Neoplasias Cutáneas/etiología , Adulto , Australia/epidemiología , Estudios de Casos y Controles , Femenino , Humanos , Incidencia , Masculino , Melanoma/epidemiología , Melanoma/metabolismo , Síndrome Metabólico/epidemiología , Persona de Mediana Edad , Noruega/epidemiología , Estudios Prospectivos , Factores de Riesgo , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/metabolismo , Suecia/epidemiología
8.
Scand J Rheumatol ; 41(3): 196-201, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22401133

RESUMEN

OBJECTIVES: To study (i) the drug utilization pattern of anti-rheumatic drugs in pregnant women and expectant fathers and (ii) the association between the use of anti-rheumatic drugs during pregnancy and the risk of congenital malformations. METHOD: Pregnancies registered in the Medical Birth Registry of Norway (MBRN) were linked to the Norwegian Prescription Database (NorPD) in the period 2004-2007. Prescriptions for anti-rheumatic drugs issued to women 3 months prior to and during pregnancy and to men 3 months prior to conception were identified. Congenital malformations were recorded according to the European Surveillance of Congenital Anomalies (EUROCAT) guidelines. RESULTS: In 154,976 singleton pregnancies, 1461 of the women (0.9%) and 1198 (0.8%) of the known fathers (150,530) were dispensed anti-rheumatic drugs at least once during the study period: 723 had non-steroidal anti-inflammatory drugs (NSAIDs), 633 prednisolone (CS), 119 sulfasalazine (SASP), 101 azathioprine (AZA), 58 hydroxychloroquine (HQC), 37 etanercept (ETAN), eight methotrexate (MTX), two leflunomide (LEF), and three adalumimab (ADA). Odds ratios (ORs) for malformations in children born of women (w) or men (m) who had received the drugs were OR(w) = 1.06 [95% confidence interval (CI) 0.85-1.32] and OR(m) = 1.19 (95% CI 0.93-1.51), respectively, and for major malformation OR(w) = 1.05 (95% CI 0.79-1.40) and OR(m) = 1.26 (95% CI 0.93-1.71), respectively. None of the children whose mother had received MTX, LEF, ETAN, or ADA were reported to be born with major malformations. CONCLUSIONS: This study revealed no major malformations of the alert drugs MTX, LEF, ETAN, or ADA. Although the numbers are limited, this provides important population-based information to both expectant parents and prescribers.


Asunto(s)
Anomalías Inducidas por Medicamentos/epidemiología , Antirreumáticos/uso terapéutico , Padre/estadística & datos numéricos , Madres/estadística & datos numéricos , Resultado del Embarazo , Anomalías Inducidas por Medicamentos/etiología , Adalimumab , Adolescente , Adulto , Anticuerpos Monoclonales Humanizados/efectos adversos , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antirreumáticos/efectos adversos , Estudios de Cohortes , Bases de Datos Factuales , Revisión de la Utilización de Medicamentos , Etanercept , Femenino , Humanos , Inmunoglobulina G/efectos adversos , Inmunoglobulina G/uso terapéutico , Isoxazoles/efectos adversos , Isoxazoles/uso terapéutico , Leflunamida , Masculino , Metotrexato/efectos adversos , Metotrexato/uso terapéutico , Persona de Mediana Edad , Noruega/epidemiología , Embarazo , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Sistema de Registros , Factores de Riesgo , Adulto Joven
9.
Ann Oncol ; 22(6): 1339-1345, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20966183

RESUMEN

BACKGROUND: Risk factors for rare gynecological cancers are largely unknown. Initial research has indicated that the metabolic syndrome (MetS) or individual components could play a role. MATERIALS AND METHODS: The Metabolic syndrome and Cancer project cohort includes 288,834 women. During an average follow-up of 11 years, 82 vulvar, 26 vaginal and 43 other rare gynecological cancers were identified. Hazard ratios (HRs) were estimated fitting Cox proportional hazards regression models for tertiles and standardized z-scores [with a mean of 0 and a standard deviation (SD) of 1] of body mass index (BMI), blood pressure, glucose, cholesterol, triglycerides and MetS. Risk estimates were corrected for random error in the measurement of metabolic factors. RESULTS: The MetS was associated with increased risk of vulvar [HR 1.78, 95% confidence interval (CI) 1.30-2.41) and vaginal cancer (HR 1.87, 95% CI 1.07-3.25). Among separate MetS components, 1 SD increase in BMI was associated with overall risk (HR 1.43, 95% CI 1.23-1.66), vulvar (HR 1.36, 95% CI 1.11-1.69) and vaginal cancer (HR 1.79, 95% CI 1.30-2.46). Blood glucose and triglyceride concentrations were associated with increased risk of vulvar cancer (HR 1.98, 95% CI 1.10-3.58 and HR 2.09, 95% CI 1.39-3.15, respectively). CONCLUSION: The results from this first prospective study on rare gynecological cancers suggest that the MetS and its individual components may play a role in the development of these tumors.


Asunto(s)
Neoplasias de los Genitales Femeninos/epidemiología , Síndrome Metabólico/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Glucemia , Presión Sanguínea , Índice de Masa Corporal , Colesterol/sangre , Femenino , Neoplasias de los Genitales Femeninos/complicaciones , Humanos , Síndrome Metabólico/sangre , Síndrome Metabólico/complicaciones , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Factores de Riesgo , Triglicéridos/sangre
10.
Eur J Neurol ; 17(12): 1445-50, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20491896

RESUMEN

BACKGROUND: Pyridostigmine is the first drug of choice for patients with myasthenia gravis (MG). The drug is not prescribed regularly to any other patient groups. We aimed to determine the prevalence, incidence and gender-specific characteristics of patients with MG needing drug treatment in a well-defined population cohort. METHODS: Data were retrieved from the Norwegian Prescription Database (NorPD) 2004-2007, containing information on all dispensed drugs in Norway. The study population comprised 677 recipients of pyridostigmine who met the following inclusion criteria (one or more): (i) More than one prescription 1 January 2004-31 December 2007, (ii) prescription from a specialist in neurology, (iii) prescription for MG being specified in NorPD. RESULTS: A total of 435 (64%) women and 242 men were included; female:male ratio 1.8:1. Point prevalence (1 January 2008) of symptomatic MG was 131 per million; 92 for men, 170 for women. Seventy-four new users of pyridostigmine were registered in 2007 (42 women, 32 men), i.e. the incidence rate for 2007 being 16 per million; 14 for men, 18 for women. Mean age of incident cases was 59 years; 64 and 55 years, respectively. Prevalence and incidence were significantly higher in the age group ≥ 50 years than < 50 years (P < 0.001), and highest at 70-79 years. Prevalence and incidence did not differ in the five geographical health regions in Norway. CONCLUSIONS: Reported prevalence and incidence are amongst the highest found in similar studies. This may be explained by optimal case identification, higher incidence of drug requiring MG amongst the elderly, and recurrences of previous MG.


Asunto(s)
Utilización de Medicamentos/estadística & datos numéricos , Miastenia Gravis/tratamiento farmacológico , Miastenia Gravis/epidemiología , Bromuro de Piridostigmina/uso terapéutico , Distribución por Edad , Estudios de Cohortes , Femenino , Humanos , Incidencia , Masculino , Noruega/epidemiología , Prevalencia , Distribución por Sexo
11.
Diabet Med ; 26(4): 404-8, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19388971

RESUMEN

AIM: To investigate, at a national level, whether patients using insulin or oral glucose-lowering agents had an increased risk of road traffic accidents compared with non-users. METHODS: All Norwegians aged 18-69 years (3.1 million) were followed from April 2004 until September 2006. Information on drug prescriptions, road traffic accidents and emigration/death was obtained from the following population-based registries: the Prescription Database, the Road Accident Registry and the Central Population Registry. The exposure period was the time from the first prescription of insulin or oral glucose-lowering agent during the study period. The incidence of accidents in the exposed person-time was compared with the incidence of accidents in the unexposed person-time by standardized incidence ratio (SIR). RESULTS: During the study period, 20 494 road traffic accidents with personal injuries were registered in Norway. One hundred and eighty-three accidents were registered for insulin users not taking oral glucose-lowering agents and 219 for users of oral blood glucose-lowering drugs without insulin. The SIR (95% confidence interval) for all ages and both genders combined were: insulin 1.4 (1.2-1.6), oral glucose-lowering agents 1.2 (1.0-1.3) and users of drugs for peptic ulcer and gastro-oesophageal reflux disease (negative comparators) 1.3 (1.2-1.4). The highest SIRs were found among the youngest insulin users (18-34 years old). CONCLUSIONS: A slightly increased risk of being involved in a road traffic accident was observed for drivers prescribed insulin, while no increased risk was observed for drivers prescribed oral glucose-lowering agents. The increased risk observed for insulin users was similar to that observed for users of drugs for peptic ulcer and gastro-oesophageal reflux disease.


Asunto(s)
Glucemia/efectos de los fármacos , Diabetes Mellitus/tratamiento farmacológico , Insulina/efectos adversos , Accidentes de Tránsito/estadística & datos numéricos , Adolescente , Adulto , Anciano , Glucemia/metabolismo , Diabetes Mellitus/epidemiología , Diabetes Mellitus/metabolismo , Métodos Epidemiológicos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Noruega/epidemiología , Adulto Joven
12.
Br J Cancer ; 99(7): 1165-9, 2008 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-18766190

RESUMEN

In this population-based Norwegian cohort study (2.1 million children), the impact of birth and parental characteristics on the risk of neuroblastoma (178 cases) was evaluated. In children below the age of 18 months, there was an increased neuroblastoma risk among those with congenital malformations and suggestion of increased risk when the mother had pre-eclampsia.


Asunto(s)
Parto Obstétrico , Neuroblastoma/epidemiología , Padres , Niño , Preescolar , Estudios de Cohortes , Humanos , Lactante , Noruega/epidemiología , Factores de Riesgo
13.
Cancer Res ; 57(18): 3989-92, 1997 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-9307283

RESUMEN

Infection with the human papillomavirus (HPV), notably HPV type 16, has been associated with esophageal cancer in seroepidemiological studies. To evaluate the consistency of the association, we performed a nested case-control study of HPV seropositivity and risk of esophageal cancer within a prospectively followed cohort of 300,000 Norwegian men and women who had donated blood samples to a serum bank. The data file of the serum bank was linked with the nationwide Cancer Registry of Norway to identify esophageal cancers diagnosed after donation of the serum sample. Fifty-seven cases and 171 matched controls were analyzed for antibodies to specific microorganisms, and odds ratios for developing esophageal cancer were calculated. There was an increased risk of developing esophageal cancer among HPV 16-seropositive subjects (odds ratio = 6.6; 95% confidence interval, 1.1-71) but not among Chlamydia trachomatis-seropositive subjects. Adjustment for the presence of serum cotinine, a marker of smoking habits, did not affect the estimates substantially. The seroepidemiological association between HPV 16 and esophageal cancer seems to be consistent in different countries.


Asunto(s)
Carcinoma de Células Escamosas/virología , Neoplasias Esofágicas/virología , Papillomaviridae/patogenicidad , Infecciones por Papillomavirus/complicaciones , Infecciones Tumorales por Virus/complicaciones , Adulto , Anciano , Anticuerpos Antibacterianos/metabolismo , Anticuerpos Antivirales/metabolismo , Carcinoma de Células Escamosas/epidemiología , Infecciones por Chlamydia/complicaciones , Chlamydia trachomatis , Neoplasias Esofágicas/epidemiología , Femenino , Humanos , Inmunoglobulina G/inmunología , Masculino , Persona de Mediana Edad , Noruega , Estudios Prospectivos
14.
Obstet Gynecol ; 95(6 Pt 2): 1006-8, 2000 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10808005

RESUMEN

BACKGROUND: Penile amputation, vaginoplasty, and clitoroplasty help male-to-female transsexuals accept their bodies and increase psychosocial function. Subsequent colpectomy is unusual. CASES: We report three patients in whom complicated, long-term problems subsequent to vaginoplasty led to total colpectomy in one case of neovaginal overgrowth of condylomata acuminata, and in two cases of colitis in rectosigmoid transplants used for neovaginoplasties. CONCLUSION: Before inversion of penile skin, in cases in which the genital skin has condylomata, the risk of condylomata overgrowth might be anticipated. Rectosigmoid vaginoplasty might result in therapy-resistent colitis, which also could lead to colpectomy.


Asunto(s)
Condiloma Acuminado/cirugía , Complicaciones Posoperatorias , Trasplante de Piel , Vagina/cirugía , Neoplasias Vaginales/cirugía , Adulto , Colitis/etiología , Femenino , Humanos , Masculino , Pene/cirugía , Transexualidad/cirugía
15.
Thyroid ; 9(3): 285-8, 1999 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10211606

RESUMEN

In animal models of carcinogenesis, pharmacological doses of dehydroepiandrosterone (DHEA) treatment appear to reduce the incidence of chemically induced thyroid cancers. DHEA and its sulfate (DHEA-S) are secreted in approximately equal amounts, but serum levels of DHEA-S are 300-500 times higher and have no diurnal variation when compared to DHEA. The hypothesis that serum concentrations of DHEA-S may be associated with thyroid cancer risk was tested in a population-based prospective case control study. Data from the practically complete nationwide Cancer Registry of Norway were linked to the data file of a serum bank comprising blood samples from 300,000 Norwegian men and women obtained through national health surveys. A total of 113 donors, who during the years after blood sampling received a diagnosis of thyroid cancer, were identified in the serum bank and were eligible for the study. Each case was matched with 3 controls. Serum levels of DHEA-S were determined blindly. Controls were divided into tertiles, and odds ratios between cases and controls were determined relative to the group with the lowest serum DHEA-S level. The risk of developing thyroid cancer was determined in women 50 years of age or older, in women below age 50, in men, and in the subgroup of 77 cases who had morphologically verified papillary thyroid cancer. No significant association between prediagnostic serum DHEA-S concentrations and thyroid cancer risk was observed. These data indicate that DHEA-S within physiological concentrations does not reduce the risk of thyroid cancer.


Asunto(s)
Carcinoma Papilar/epidemiología , Sulfato de Deshidroepiandrosterona/sangre , Neoplasias de la Tiroides/epidemiología , Adulto , Factores de Edad , Carcinoma Papilar/sangre , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Estudios Prospectivos , Medición de Riesgo , Factores Sexuales , Neoplasias de la Tiroides/sangre
16.
Eur J Clin Nutr ; 52(4): 271-8, 1998 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9578339

RESUMEN

OBJECTIVE: The aim of the present study was to elucidate the influence of social, dietary and environmental factors on the incidence of malignant epithelial tumours in the upper digestive tract and on the prognosis of patients with these cancers. DESIGN: A population-based case-control study was carried out, and the patients in the study were included in a survival analysis. SETTING: The study was carried out at the Department of Otorhinolaryngology at Ullevål University Hospital, Oslo, Norway. SUBJECTS: In the case-control study, 84 patients and 89 controls were included. Only the patients were included in the survival analysis. RESULTS: Smoking showed the highest odds ratio (OR) for morbidity (OR = 29). The patients had in general a lower social status, and a higher alcohol intake (OR = 6.6). For both beta-carotene and vitamin C, the ORs decreased with increasing intake (OR = 0.2 and 0.3, respectively). Increased ORs were associated with low values for haemoglobin, iron, TIBC, folic acid, magnesium and especially for albumin (OR = 14), and with high values for ferritin, vitamin B12 and thiocyanate (a marker for smoking). Stage of the disease was an important prognostic factor. The relative risk (RR) of dying for disseminated vs localised tumours being 3.2. A poorer prognosis was linked to higher age, to smoking vs no smoking (RR = 2.3), and to lower levels of haemoglobin, albumin, magnesium and thiocyanate. CONCLUSIONS: Strong beer, liquor, consumption of milk and table fat, low social status and smoking seemed to have a negative impact on both disease and survival. Fruit and vegetables might, however, reduce the risk. Whereas low serum albumin, iron and magnesium indicated a high OR for cancer, vitamin C and beta-carotene had the opposite implication. No significant implications on survival could be detected in blood chemistry beyond the stage of disease.


Asunto(s)
Carcinoma/epidemiología , Dieta , Neoplasias del Sistema Digestivo/epidemiología , Adulto , Anciano , Consumo de Bebidas Alcohólicas/efectos adversos , Ácido Ascórbico/administración & dosificación , Carcinoma/mortalidad , Estudios de Casos y Controles , Grasas de la Dieta/administración & dosificación , Neoplasias del Sistema Digestivo/mortalidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Noruega/epidemiología , Pronóstico , Fumar/efectos adversos , Clase Social , Análisis de Supervivencia , beta Caroteno/administración & dosificación
17.
Scand J Work Environ Health ; 25 Suppl 2: 1-116, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10507118

RESUMEN

This report presents 20 years' of cancer incidence data by occupational group for the Nordic populations. The study covers the 10 million people aged 25-64 years at the time of the 1970 censuses in Denmark, Finland, Norway, and Sweden, and the 1 million incident cancer cases diagnosed among these people during the subsequent 20 years. The project was undertaken as a cohort study with linkage of individual records based on the personal identification numbers used in all the Nordic countries. In the 1970 censuses, information on occupation for each economically active member of the household was provided in free text in self-administered questionnaires. The data were centrally coded and computerized in the statistical offices. Norway, Sweden, and Finland used the Nordic Classification of Occupations, while Denmark used a national coding scheme. However, all the data could be reclassified into 53 occupational groups and 1 group of economically inactive persons. Person-years at risk were accumulated from 1 January 1971 until the date of emigration, date of death or 31 December 1987 in Denmark, 1989 in Sweden, 1990 in Finland, and 1991 in Norway. The 4 countries all had nationwide registration of incident cancer cases during the entire study period. All incident cancer cases during the individual risk periods were included in the analysis. Despite minor differences between the countries, the International Classification of Diseases, 7th revision, formed the core basis for the diagnostic coding in all 4 countries. For the present study the incident cancer cases have been classified into 35 broad diagnostic groups. The observed number of cancer cases in each group of persons defined by country, gender, and occupation was compared with the expected number calculated from the age-, gender-, and period-specific person-years and the incidence rates for the national population. The result has been presented as a standardized incidence ratio (SIR), defined as the observed number of cases divided by the expected number and multiplied by 100. In the tables of this report, all the SIR values for which the upper limit of the 95% confidence interval is below 100 are printed in green and all those for which the lower limit of the confidence interval is above 100 are printed in red. For all cancers combined, the study showed a wide variation among the men, from an SIR of 79 for farmers to 159 for waiters. The occupations with the highest SIR values also included seamen and workers producing beverages and tobacco. Among the women the SIR values varied from 83 for gardeners to 129 for tobacco workers. Low SIR values were found for farmers and teachers. Outdoor workers such as fishermen and gardeners had the highest risk of lip cancer, while the lowest risk was found among indoor workers such as physicians and artistic workers. Almost all pleural cancers are associated with asbestos exposure. Accordingly, plumbers, welders, mechanics, and seamen were the occupations with the highest risk. There was also an excess risk of pleural cancer in the occupational group of technical, chemical, physical, and biological workers, including, among others, engineers and chemists potentially exposed to asbestos. The wood workers included in the present study had the highest risk of nasal cancer. Most studies of nasal cancer have shown increased risks associated with exposure to wood dust, both for those in furniture making and for those exposed exclusively to soft wood. Nickel refinery workers are also known for their high risk of nasal cancer. In the present study they were included in the occupational group of smelting workers. Lung cancer was the most frequent cancer among men in the present study. Tobacco smoking is the major risk factor for this disease, but occupational exposures also play an important role. Waiters and tobacco workers had the highest risk of lung cancer. Miners and quarry workers also had a high risk of lung cancer, which may be related to


Asunto(s)
Neoplasias/epidemiología , Neoplasias/etiología , Enfermedades Profesionales/epidemiología , Enfermedades Profesionales/etiología , Adulto , Distribución por Edad , Monitoreo del Ambiente , Monitoreo Epidemiológico , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Exposición Profesional/efectos adversos , Exposición Profesional/análisis , Ocupaciones/estadística & datos numéricos , Vigilancia de la Población , Factores de Riesgo , Países Escandinavos y Nórdicos/epidemiología , Distribución por Sexo
18.
Equine Vet J ; 26(2): 152-5, 1994 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-8575380

RESUMEN

Radiographic examination of the metacarpo- and metatarsophalangeal joints was performed on 753 Standardbred trotters (6-21 months of age): 21 showed obvious changes in 26 proximal sesamoid bones on lateromedial projection. The radiographic changes were divided into 6 different types: (1) irregular abaxial margin (8 horses); (2) enlargement of the sesamoid bone (6 horses); (3) 'fracture' or separate centre of ossification of the apex (4 horses); (4) vertical, non-articular fracture of the plantar part of the sesamoid bone (1 horse); (5) a small bony fragment located in a defect in the apical part of the bone (2 horses); and (6) multiple areas of decreased radiodensity (1 horse). Each horse displayed only one type of radiographic change except for one which possessed those of types 3 and 5. Follow-up radiographic examination of 21 of the 26 affected proximal sesamoid bones at approximately 6-month intervals revealed a reduction in the changes in 13 bones and an unaltered condition in 8. Lameness examination was performed on 16 of the 21 horses at 3 years of age and 14 (87.5%) were observed to be lame, but detected lameness did not seem to be referrable to the sesamoid changes. Earnings after the racing season as 3- and 4-year-old horses showed no differences (P > 0.05) between horses with radiographic changes in the proximal sesamoid bones and those without such changes.


Asunto(s)
Caballos/fisiología , Cojera Animal/fisiopatología , Condicionamiento Físico Animal/fisiología , Esfuerzo Físico/fisiología , Huesos Sesamoideos/diagnóstico por imagen , Animales , Progresión de la Enfermedad , Femenino , Caballos/anatomía & histología , Cojera Animal/etiología , Masculino , Radiografía , Huesos Sesamoideos/anatomía & histología , Huesos Sesamoideos/fisiología
20.
J Am Vet Med Assoc ; 206(7): 1013-7, 1995 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-7768708

RESUMEN

The tarsocrural, metacarpophalangeal, and metatarsophalangeal joints of 753 Standardbred yearlings were radiographed. On the basis of radiographic findings, the horses were allotted into 4 groups. Group-1 horses had osteochondrosis in the tarsocrural joints. Group-2 horses had palmar/plantar bony fragments in the metacarpo- and metatarsophalangeal joints. Group-3 horses had radiographic changes in the metacarpo- and metatarsophalangeal joint region, such as bony fragments located at the dorsoproximal end of the proximal phalanx, osteochondrosis of the sagittal ridge of the third metacarpus/metatarsus, ununited proximoplantar tuberosity of the proximal phalanx, or nonarticular, osteolytic and productive changes in the proximal sesamoid bones. Group-4 horses did not have radiographic changes. The number of race starts and race earnings (categorized) of the horses in groups 1, 2, and 3 were compared with those of the horses in group 4, using a multivariate regression analysis. Horses in groups 1, 2, and 3 had significantly fewer starts and somewhat lower earnings compared with the horses in group 4.


Asunto(s)
Carpo Animal/diagnóstico por imagen , Enfermedades de los Caballos/diagnóstico por imagen , Osteocondritis/veterinaria , Condicionamiento Físico Animal , Tarso Animal/diagnóstico por imagen , Animales , Artrografía/veterinaria , Cruzamiento , Carpo Animal/patología , Femenino , Enfermedades de los Caballos/economía , Caballos , Masculino , Osteocondritis/diagnóstico por imagen , Osteocondritis/economía , Deportes , Tarso Animal/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA